Alzheimer’s disease (AD), Parkinson’s disease (PD) and glaucoma are all regarded as neurodegenerative diseases (neuro-DDs) because these diseases are highly related to the degeneration loss of functions and death of neurons with aging. The conventional diagnostic methods such as neuroimaging for these diseases are not only expensive but also time-consuming, resulting in significant financial burdens for patients and public health challenge for nations around the world. Hence early detection of neuro-DDs in a cost-effective and rapid manner is critically needed. For the past decades, some chip-based detection technologies have been developed to address this challenge, showing great potential in achieving point-of-care (POC) diagnostics of neuro-DDs. In this review, chip-based detection of neuro-DDs’ biomarkers enabled by different transducing mechanisms is evaluated.

中文翻译：

---

片上神经退行性疾病生物标记物的检测：技术和前景。

阿尔茨海默氏病（AD），帕金森氏病（PD）和青光眼均被视为神经退行性疾病（neuro-DDs），因为这些疾病与衰老的神经元功能退化和死亡高度相关。用于这些疾病的常规诊断方法（如神经影像学）不仅昂贵，而且费时，从而给患者带来了沉重的经济负担，并给世界各国带来了公共卫生挑战。因此，迫切需要以经济有效的方式早期检测神经-DDs。在过去的几十年中，已经开发了一些基于芯片的检测技术来应对这一挑战，显示出在实现神经DD的即时诊断（POC）诊断方面的巨大潜力。在这篇评论中